Amgen, NantWorks deal

Amgen granted NantWorks’ NantPharma LLC subsidiary exclusive, worldwide rights to develop and commercialize AMG 337, excluding Japan, Russia and certain countries in central Asia. AMG 337, a small molecule inhibitor of c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene), is in Phase II testing to treat gastric and esophageal cancers. NantPharma said it will select clinical trial patients based on molecular profiling. ...